ライフサイエンスコーパス: erectile

1 exual life, while 26% reported impairment in erectile and 22% in ejaculatory function.

2 strated to be an independent risk factor for erectile and ejaculatory dysfunction.

3 ng sexual desire, sexual function, including erectile and ejaculatory function, and sexual satisfacti

4 , the external layer, which supplements both erectile and micturition function, the internal layer, w

5 Urinary incontinence and erectile and sexual dysfunction were each greater with s

6 le lubricating (273 [22.3%]) among women and erectile difficulties (156 [21.7%]) and lack of interest

7 men, the most prevalent sexual problems were erectile difficulties (37%).

8 s associated with ischemic tissue damage and erectile disability.

9 apism, an important but poorly characterized erectile disorder.

10 athway may be a novel therapeutic target for erectile disorders.

11 , 2.04-2.46), hypotension (3.23, 1.85-5.52), erectile dysfunction (1.30, 1.11-1.51), urinary dysfunct

12 9 vs 12.2 per 100 person-years; P = .02) and erectile dysfunction (26.8 vs 19.2 per 100 person-years;

13 d ratio 1.03 [95% CI 0.88-1.21]; p=0.72) and erectile dysfunction (272 [1.86% per annum] vs 302 [2.14

14 3) but more likely to receive a diagnosis of erectile dysfunction (absolute risk, 5.9 vs 5.3 per 100

15 ked at some time had a greater likelihood of erectile dysfunction (age-adjusted odds ratio = 1.42, 95

16 0.008) for participants with first onset of erectile dysfunction (before 1986) at 60 or more, 50-59,

17 D) risk factors measured in mid-life predict erectile dysfunction (ED) 25 years later.

18 he internal pudendal arteries among men with erectile dysfunction (ED) and a suboptimal response to p

19 to determine whether patients with vascular erectile dysfunction (ED) and no other clinical cardiova

20 Chronic heart failure (HF) and erectile dysfunction (ED) are 2 highly prevalent disorde

21 Erectile dysfunction (ED) carries an independent risk fo

22 Pharmacologic treatments for erectile dysfunction (ED) have gained popularity among m

23 Erectile dysfunction (ED) is estimated to affect more th

24 The predominant etiology for erectile dysfunction (ED) is vascular, but limited data

25 This study was designed to determine whether erectile dysfunction (ED) predicts cardiovascular diseas

26 hough there are plausible mechanisms linking erectile dysfunction (ED) with coronary heart disease (C

27 terase-5 inhibitor used for the treatment of erectile dysfunction (ED), on the QT interval.

28 accounts significantly for the prevalence of erectile dysfunction (ED).

29 degeneration of the cavernous nerve (CN) and erectile dysfunction (ED).

30 osis, which is relevant to the occurrence of erectile dysfunction (ED).

31 less legs syndrome (RLS) was associated with erectile dysfunction (ED).

32 ers, and both share common risk factors with erectile dysfunction (ED).

33 treatment in the management of patients with erectile dysfunction (Grade: insufficient evidence to de

34 ibitors such as 2a for potential use in male erectile dysfunction (MED).

35 (P < .001), urinary function (P = .003), and erectile dysfunction (P = .008); by 3 years, however, th

36 to enhance sex (p=0.0006), use of drugs for erectile dysfunction (p<0.0001), and 100% condom use (p<

37 lation between cigarette smoking and risk of erectile dysfunction (p(trend) = 0.005).

38 lockbuster status in the treatment of penile erectile dysfunction (PED).

39 nary retention (three [2%] vs one [<1%]) and erectile dysfunction (two [1%] vs three [1%]).

40 function tenderness, frequent urination, and erectile dysfunction [ED]) and measures of physical and

41 tudy entry, 2420 men (57%) reported incident erectile dysfunction after 5 years.

42 morbidities may have a significant impact on erectile dysfunction after CaP treatment.

43 d tools to enable personalized prediction of erectile dysfunction after prostate cancer treatment are

44 Tadalafil is used to treat erectile dysfunction after prostate cancer treatment, bu

45 Erectile dysfunction after radical therapy for CaP may b

46 iation between cigarette smoking and risk of erectile dysfunction among 7,684 Chinese men aged 35-74

47 Erectile dysfunction and cardiovascular disease share th

48 e the foundation for the strong link between erectile dysfunction and cardiovascular disease.

49 els were used to evaluate the association of erectile dysfunction and cardiovascular disease.

50 etermine associations between stroke-related erectile dysfunction and cerebral ischaemic lesion sites

51 Erectile dysfunction and depression are highly associate

52 l treatment of tumors with NI often leads to erectile dysfunction and deteriorated quality of life.

53 A/Rho-kinase contributes to diabetes-related erectile dysfunction and down-regulation of eNOS in the

54 ng evidence for an association between LUTS, erectile dysfunction and ejaculatory dysfunction.

55 orts the link between metabolic syndrome and erectile dysfunction and highlights metabolic syndrome a

56 dities associated with prostatectomy, namely erectile dysfunction and incontinence.

57 s showed associations between stroke-related erectile dysfunction and lesion sites in the right occip

58 Erectile dysfunction and low testosterone levels frequen

59 o in improving erectile function in men with erectile dysfunction and low testosterone levels.

60 odiesterase that is used clinically to treat erectile dysfunction and pulmonary arterial hypertension

61 tadalafil, which are drugs for treatment of erectile dysfunction and pulmonary hypertension.

62 inary incontinence, anastomotic contracture, erectile dysfunction and rectourethral fistula (RUF) for

63 afety and efficacy of vardenafil in men with erectile dysfunction and untreated mild depression.

64 tolerated and highly efficacious in men with erectile dysfunction and untreated mild major depression

65 DE-5 inhibitor in men who seek treatment for erectile dysfunction and who do not have a contraindicat

66 Erectile dysfunction appears to be one of the earliest s

67 ival rate for unifocal disease, and rates of erectile dysfunction are dramatically lower than those s

68 ng evidence that endothelial dysfunction and erectile dysfunction are linked.

69 risk factors for cardiovascular disease and erectile dysfunction are similar.

70 phosphodiesterase-5 inhibitor treatment for erectile dysfunction associated with antidepressant ther

71 going prostatectomy were more likely to have erectile dysfunction at 2 years (odds ratio, 3.46; 95% C

72 was 0.015 per person-year among men without erectile dysfunction at study entry and was 0.024 per pe

73 Among the 4247 men without erectile dysfunction at study entry, 2420 men (57%) repo

74 at study entry; of these men, 3816 (47%) had erectile dysfunction at study entry.

75 y and was 0.024 per person-year for men with erectile dysfunction at study entry.

76 Men with erectile dysfunction before 1986 were 3.8 times more lik

77 very 3 months for cardiovascular disease and erectile dysfunction between 1994 and 2003.

78 nhibitors of PDE5 such as sildenafil correct erectile dysfunction by augmenting cGMP-mediated vascula

79 association is causal, an estimated 22.7% of erectile dysfunction cases (11.8 million cases) among Ch

80 he International Index of Erectile Function (Erectile Dysfunction Domain) score >/= 4 points in >/= 5

81 tes, 477 (21%) used cannabis, 460 (21%) used erectile dysfunction drugs, 453 (20%) used cocaine, 280

82 The target for the oral erectile dysfunction drugs, phosphodiesterase type 5 (PD

83 tion therapy for ischemic and any stroke and erectile dysfunction for any stroke.

84 llel-group, double-blind study, 280 men with erectile dysfunction for at least 6 months and untreated

85 he technology used intraoperatively, induces erectile dysfunction for most men who undergo the proced

86 is to update the results of the only phase 1 erectile dysfunction gene transfer trial and based upon

87 Erectile dysfunction has a negative impact on health-rel

88 with potential utility for the treatment of erectile dysfunction has been discovered, guided by the

89 understanding of the cause and management of erectile dysfunction in CaP survivors.

90 synthase (eNOS) function is associated with erectile dysfunction in diabetes mellitus, but the exact

91 etrospective questionnaire with questions on erectile dysfunction in different time periods.

92 Although no standard management of erectile dysfunction in prostate cancer (CaP) survivors

93 ot support daily use of tadalafil to prevent erectile dysfunction in these patients.

94 Erectile dysfunction is a harbinger of cardiovascular cl

95 Erectile dysfunction is also strongly associated with a

96 Erectile dysfunction is common after radical prostatecto

97 Erectile dysfunction is common among individuals with Pa

98 the influence of CP/CPPS on the incidence of erectile dysfunction is scant.

99 Erectile dysfunction occurred frequently after all treat

100 tain patients who already have some baseline erectile dysfunction or are not candidates for nerve-spa

101 Erectile dysfunction rates are universally high after wh

102 f this work is to review the fundamentals of erectile dysfunction relevant to the postprostatectomy p

103 gression analysis showed that stroke-related erectile dysfunction remained associated with lesions of

104 ased lesion analysis, the difference between erectile dysfunction scores before and after stroke was

105 as brain volumes and the difference between erectile dysfunction scores before and after stroke.

106 In 32 patients (61.5%) erectile dysfunction scores declined after the stroke an

107 Deterioration of erectile dysfunction scores was not associated with pati

108 Erectile dysfunction should be included as an outcome in

109 Erectile dysfunction should prompt investigation and int

110 ata linking lower urinary tract symptoms and erectile dysfunction suggest that lower urinary tract sy

111 vent of oral medication for the treatment of erectile dysfunction the disease has garnered increasing

112 Erectile dysfunction treatment should be considered a co

113 T vs no ADT and 1.35 (95% CI, 1.18-1.53) for erectile dysfunction vs no dysfunction.

114 and hypercholesterolemia, the odds ratio of erectile dysfunction was 1.41 (95% confidence interval (

115 ire; during the fourth biennial examination, erectile dysfunction was assessed with the Brief Male Se

116 After adjustment, incident erectile dysfunction was associated with a hazard ratio

117 rge cohort of men, the authors observed that erectile dysfunction was associated with a higher risk o

118 this question, the authors examined whether erectile dysfunction was associated with Parkinson's dis

119 The association between smoking and erectile dysfunction was evaluated in a cohort of 2,115

120 Multivariate-adjusted odds ratios of erectile dysfunction were 1.27 (95% CI: 0.91, 1.77), 1.4

121 Cigarette smoking and erectile dysfunction were assessed by questionnaire.

122 ica albuginea, is reserved for patients with erectile dysfunction who have not responded to medical t

123 ir forties had the greatest relative odds of erectile dysfunction, 2.74 (95% confidence interval (CI)

124 e efforts being made to reduce posttreatment erectile dysfunction, a major morbidity of these therapi

125 phosphodiesterase 5 inhibitor used to treat erectile dysfunction, ameliorates high glucose stimulati

126 ab infusion, a second patient had persistent erectile dysfunction, and a third patient died of a haem

127 rapeutic target for the treatment of asthma, erectile dysfunction, and atherosclerosis.

128 and infertility in women and loss of libido, erectile dysfunction, and infertility in men; they are g

129 isorders including congestive heart failure, erectile dysfunction, and inflammation.

130 failure like infertility, low testosterone, erectile dysfunction, and low bone mineral density.

131 apter, including fertility, gonadal failure, erectile dysfunction, and menstrual issues in SCD.

132 degree of curvature, the type of deformity, erectile dysfunction, and penile length are all characte

133 er symptoms may include depression, fatigue, erectile dysfunction, and reduced muscle strength/mass.

134 rome, sudden deafness, hepatorenal syndrome, erectile dysfunction, and so on.

135 Bowel continence, erectile dysfunction, and social life disturbance were n

136 such as sildenafil are widely used to treat erectile dysfunction, but growing evidence supports impo

137 ole of endothelium in the pathophysiology of erectile dysfunction, cardiovascular disease, and the me

138 Other comorbidities including erectile dysfunction, cardiovascular diseases should als

139 of energy, depressed mood, decreased libido, erectile dysfunction, decreased muscle mass and strength

140 Erectile dysfunction, defined as the consistent inabilit

141 In patients with refractory erectile dysfunction, dexterous and motivated patients r

142 logical conditions including asthma, cancer, erectile dysfunction, glaucoma, insulin resistance, kidn

143 levels such as hot flushes, lack of libido, erectile dysfunction, gynecomastia and bone mineral dens

144 s of gastrointestinal and urinary morbidity, erectile dysfunction, hip fractures, and additional canc

145 of poor morning erection, low sexual desire, erectile dysfunction, inability to perform vigorous acti

146 or on the individual preferences of men with erectile dysfunction, including ease of use, cost of med

147 Risks of erectile dysfunction, incontinence, and disease recurren

148 applications (such as myocardial infarction, erectile dysfunction, multiple sclerosis, etc.) in addit

149 disease, obstructive sleep apnoea syndrome, erectile dysfunction, periodontitis, inflammatory bowel

150 prespecified AEs of interest-muscle-related, erectile dysfunction, sleep disturbance, and cognitive i

151 are multifactorial and include hypogonadism, erectile dysfunction, sperm abnormalities, and complicat

152 in the advent of PDE5 inhibitors that treat erectile dysfunction, such as Viagra, Levitra, and Ciali

153 duced over 30 years ago for the treatment of erectile dysfunction, technological innovations have con

154 For men with either incident or prevalent erectile dysfunction, the hazard ratio was 1.45 (95% CI,

155 nt, to assess and treat side-effects such as erectile dysfunction, to switch to less costly generic a

156 tonomic features (constipation, hypotension, erectile dysfunction, urinary dysfunction, and dizziness

157 ccess of PDE5 inhibitors in the treatment of erectile dysfunction.

158 ng would each result in 1 additional case of erectile dysfunction.

159 rted use of medications or other devices for erectile dysfunction.

160 emain a viable tertiary treatment option for erectile dysfunction.

161 such as asthma, cardiovascular diseases, and erectile dysfunction.

162 ibitors in patients with coexisting LUTS and erectile dysfunction.

163 atic hypotension, sweating abnormalities, or erectile dysfunction.

164 denafil, etc.) are first-line treatments for erectile dysfunction.

165 -eye movement sleep behaviour disorder), and erectile dysfunction.

166 nitourinary complications, incontinence, and erectile dysfunction.

167 ssociation with penile fibrosis and eventual erectile dysfunction.

168 l testing in and pharmacologic management of erectile dysfunction.

169 diated erectile tissue damage and subsequent erectile dysfunction.

170 wer administered dosage for the treatment of erectile dysfunction.

171 cular diseases to pulmonary hypertension and erectile dysfunction.

172 lation between cigarette smoking and risk of erectile dysfunction.

173 age, respectively, relative to those without erectile dysfunction.

174 PDE V inhibitor that is used clinically for erectile dysfunction.

175 ment or prophylaxis exists for posttreatment erectile dysfunction.

176 1a (ABT-724) for the potential treatment of erectile dysfunction.

177 potential risk factor for the development of erectile dysfunction.

178 onent of therapy for men with depression and erectile dysfunction.

179 low quality of life contributes to or causes erectile dysfunction.

180 static hyperplasia are definitely related to erectile dysfunction.

181 This effect has led to its use for treating erectile dysfunction.

182 escribing an association between smoking and erectile dysfunction.

183 and it is this that contributes to or causes erectile dysfunction.

184 unction, and loss of the BK channel leads to erectile dysfunction.

185 clinical endpoints: late rectal bleeding and erectile dysfunction.

186 836 had previously smoked, and 203 reported erectile dysfunction.

187 ion-making when confronted by a patient with erectile dysfunction.

188 and is effective in patients suffering from erectile dysfunction.

189 ABT-724 could be useful for the treatment of erectile dysfunction.

190 raction, such as hypertension, glaucoma, and erectile dysfunction.

191 ated with devastating complications, notably erectile dysfunction.

192 the stroke and therefore had stroke-related erectile dysfunction.

193 One patient in each group reported erectile dysfunction.

194 pisodic dry eyes and mouth, hot flashes, and erectile dysfunction.

195 ion, implying unique approaches for treating erectile dysfunction.

196 ) increases cGMP and is used widely to treat erectile dysfunction; however, its role in the heart and

197 l morbidity and fewer hip fractures but more erectile dysfunction; IMRT compared with proton therapy

198 as improvement in the International Index of Erectile Function (Erectile Dysfunction Domain) score >/

199 ostvoid residual volume, International Index Erectile Function (IIEF) score, prostate volume, and pro

200 asked to complete the International Index of Erectile Function (IIEF-5), which allows stratification

201 re surgery and during follow-up and measured erectile function (International Index for Erectile Func

202 the follow-up than were those with very good erectile function (relative risk = 3.8, 95% confidence i

203 and treatment details enables prediction of erectile function 2 years after prostatectomy, external

204 Primary outcome was off-drug spontaneous erectile function 28 to 30 weeks after radiotherapy star

205 d erectile function (International Index for Erectile Function [IIEF] score) and urine flow rates at

206 th first-ever ischaemic strokes, we assessed erectile function after and retrospectively 3 months pri

207 mproved recovery of urinary incontinence and erectile function after open radical prostatectomy.

208 l-wise analysis indicates that deteriorating erectile function after stroke is associated with lesion

209 of patients with unchanged and deteriorated erectile function after stroke.

210 +/- 8.7 versus 11.9 +/- 10.2 (P < 0.05) for erectile function and 6.9 +/- 2.4 versus 5.3 +/- 2.5 (P

211 Significant improvements in erectile function and depression were observed in patien

212 showed associations between deterioration of erectile function and lesion sites in the right occipita

213 ermittent therapy was associated with better erectile function and mental health (P<0.001 and P=0.003

214 To optimize recovery of erectile function and prevent loss of penile length, pen

215 and endothelial NOS-deficient mice maintain erectile function and reproductive capacity, questioning

216 The critical maneuvers to preserving erectile function are atraumatic dissection of the prost

217 ious and otherwise) and urinary symptoms and erectile function assessed using patient questionnaires.

218 Among men who reported their erectile function before 1986, 200 were diagnosed with P

219 -88%) assigned to receive tadalafil retained erectile function between weeks 28 and 30 compared with

220 sphodiesterase-5 inhibitors (PDE5Is) improve erectile function by enhancing nitric oxide availability

221 autologous SIS-ADSC grafts maintained better erectile function compared with animals grafted with SIS

222 tributing to male sexual function may impair erectile function depending on the lesion site.

223 conduction, activities of daily living, and erectile function did not show a significant difference

224 ded International Index of Erectile Function erectile function domain and 17-item Hamilton Depression

225 The International Index of Erectile Function erectile function domain score was 22.9 with vardenafil

226 in International Index of Erectile Function erectile function domain score was the most important pr

227 In order to optimize postprostatectomy erectile function during a robotic-assisted radical pros

228 n together, these data suggest that impaired erectile function during the aging process involves incr

229 Endpoints included International Index of Erectile Function erectile function domain and 17-item H

230 The International Index of Erectile Function erectile function domain score was 22.

231 Improvement in International Index of Erectile Function erectile function domain score was the

232 riable logistic regression models predicting erectile function estimated 2-year function probabilitie

233 Participants rated their erectile function in 2000 (with historical reporting fro

234 and young rats for 7 days markedly improved erectile function in aged rats when compared with that i

235 protein content and activity thus restoring erectile function in diabetes.

236 rior to sildenafil plus placebo in improving erectile function in men with erectile dysfunction and l

237 TCMV19NRhoA) on RhoA/Rho-kinase and eNOS and erectile function in vivo in the STZ-diabetic rat.

238 ry goal of radical prostatectomy, preserving erectile function is also tantamount, given the indolent

239 fficacy in motivated patients, the return of erectile function is never guaranteed with nonsurgical m

240 ions but also return him to his preoperative erectile function level.

241 and clinically meaningful improvement in all erectile function parameters.

242 t or after radical prostatectomy to maximize erectile function recovery.

243 dical prostatectomy as a strategy to improve erectile function recovery.

244 radical prostatectomy are of some benefit to erectile function recovery.

245 Participant-reported International Index of Erectile Function response before radiotherapy and at we

246 o hundred forty-two participants with intact erectile function scheduled to receive radiotherapy for

247 d) and aged (20-22 month old) rats underwent erectile function testing in vivo by measuring intracave

248 1027) were used to develop models predicting erectile function that were externally validated among 1

249 Erectile function was assessed by means of questionnaire

250 The data demonstrated that erectile function was significantly lower in aged rats t

251 Whether testosterone could improve erectile function without sildenafil was not studied.

252 nction deteriorated with age (odds ratio for erectile function, 0.40 per 10-year increase in age; 95%

253 ostate Symptom Score, International Index of Erectile Function, and Female Sexual Function Index), an

254 that the BK channel has an important role in erectile function, and loss of the BK channel leads to e

255 europathy and endothelial dysfunction impair erectile function, and phosphodiesterase inhibition prod

256 regarding oncologic outcome, continence, and erectile function, as well as some earlier manuscripts t

257 Since it may permanently impair erectile function, it must be managed and treated as soo

258 Sexual desire, erectile function, overall sexual function scores, partn

259 laxing factors involved in the regulation of erectile function, providing alternative therapeutic tar

260 10) were normal, showing normal voiding and erectile function, respectively.

261 Inhibition of this pathway attenuated erectile function, suggesting that EETs are required for

262 Median overall International Index of Erectile Function-15 (IIEF-15) scores were similar at ba

263 scores of the 5-item International Index of Erectile Function-5 questionnaire.

264 , urinary problems, hot flashes, libido, and erectile function.

265 TA reconstruction procedures and can restore erectile function.

266 in both subjective and objective measures of erectile function.

267 ivities of daily living, quality of life and erectile function.

268 izations, health-related quality of life, or erectile function.

269 e surrounding fascia, may hasten recovery of erectile function.

270 ost important predictor for return to normal erectile function.

271 tric oxide, which plays an important role in erectile function.

272 ecovery is primarily dictated by recovery of erectile function.

273 examined associations between flavonoids and erectile function.

274 as significantly increased sexual desire and erectile function.

275 rolling disease while preserving urinary and erectile function.

276 ared with placebo did not result in improved erectile function.

277 mooth muscle tissue is the key to preserving erectile function.

278 -flow priapism and for restoration of penile erectile function.

279 of the neurovascular bundle responsible for erectile function.

280 raxia enables earlier and better recovery of erectile function.

281 ed higher than baseline, although persistent erectile impairment was limited to Caucasian American pa

282 mol/kg, with a positive response rate of 77% erectile incidence.

283 Urinary, bowel, and erectile morbidity rates were 33.8%, 21.0%, and 16.7%, r

284 Erectile morbidity was associated with younger age (P <

285 ed percentage of men reporting posttreatment erectile or ejaculatory problems remained higher than ba

286 aseline and 12 months were noted for IIEF-15 erectile (p=0.042) and orgasmic function (p=0.003).

287 ding bat, Glossophaga soricina, uses dynamic erectile papillae to collect nectar.

288 P-dependent phosphorylation of nNOS mediates erectile physiology, including sustained erection.

289 with CRC the most during the past week were erectile problems (42% of men), trouble hearing (11%), t

290 tudy was to examine the relationship between erectile problems in men and cardiovascular disease (CVD

291 There was a significant decrease in erectile response to cavernosal nerve stimulation in the

292 Erectile response to shear stress elicited by ES and to

293 behavior, obesity, energy homeostasis, male erectile response, and blood pressure.

294 n the enzyme and hampering mechanisms of the erectile response.

295 AAVT19NRhoA gene transfer improved erectile responses in the STZ-diabetic rat to values sim

296 Erectile responses to both cavernous nerve stimulation a

297 avernosal tissue preservation and maintained erectile responses, similar to controls, in a rat model

298 ed NO release from C6' corrects pathological erectile signaling in mouse models of priapism and sugge

299 30% and 40% in mean diameter in flaccid and erectile states, respectively.

300 tation, is associated with ischemia-mediated erectile tissue damage and subsequent erectile dysfuncti